Study to investigate KBL697 (Lactobacillus gasseri) in patients with mild to moderate active ulcerative colitis.

Currently recruiting

About this study

In this research project, we are testing a new treatment for mild to moderate active ulcerative colitis. The new treatment uses a type of bacteria called KBL697 (Lactobacillus gasseri). The study aims to learn how effective and safe the bacteria is in the treatment of people with mild to moderate active ulcerative colitis.

Anticipated enrolment close date: August 2026

Contact the Clinical Trials Centre for more information.

Contact us to find out more about this research study, quoting reference number 2021.188

Who can take part

Inclusion criteria

  • Aged 18 to 75 years
  • Person has been diagnosed with ulcerative colitis for more than 3 months
  • Have mild to moderate disease assessed by specialists

Exclusion criteria

  • Possibility of another inflammatory bowel disease such as Crohn’s disease
  • Patient has any immunosuppressant diseases

What's involved

There is a total of seven visits over about 17 weeks

Main procedures include:

  • Medical history
  • Physical exam
  • Electrocardiogram (ECG)
  • Weight
  • Height
  • Blood pressure
  • Pulse
  • Heart rate
  • Health questionnaires
  • Blood samples
  • Stool samples
  • Flexible sigmoidoscopy
  • Biopsy
Person handling test tubes for research


All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.

This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.